GURU.Markets stock price, segment price, and overall market index valuation
The company's share price PROCEPT BioRobotics
PROCEPT BioRobotics has revolutionized prostate adenoma treatment with its AquaBeam robotic system. Its stock price reflects the rapid growth of this technology. This chart tells the story of a medical breakthrough that is changing the standard of surgical treatment.
Share prices of companies in the market segment - Therapeutic medical equipment
PROCEPT is the manufacturer of the AquaBeam robotic system for minimally invasive prostate treatment. We classify it as a member of the Therapeutic Medical Equipment sector, and the graph below shows the dynamics of the entire medical robotics industry, where it successfully competes.
Broad Market Index - GURU.Markets
PROCEPT BioRobotics has developed the AquaBeam robotic system for minimally invasive prostate treatment. Its innovative technology makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how PROCEPT compares to it.
Change in the price of a company, segment, and market as a whole per day
PRCT - Daily change in the company's share price PROCEPT BioRobotics
Shares of PROCEPT BioRobotics, a developer of surgical robots, exhibit the volatility typical of the medical technology sector. change_co measures the market's reaction to sales data and regulatory news. This metric is important for building models for analyzing innovative medical companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Therapeutic medical equipment
PROCEPT BioRobotics Corporation is a company in the medical device sector. This chart shows the average daily volatility of the MedTech industry. Comparing it to PRCT, which focuses on robotic surgery, helps assess whether its innovative products make it more or less volatile than the sector.
Daily change in the price of a broad market stock, index - GURU.Markets
PROCEPT BioRobotics is the manufacturer of the AquaBeam robotic surgical system for prostate treatment. The robotic surgery market is growing rapidly. The chart below shows the volatility in the medical technology sector, helping to assess how PROCEPT shares are responding to innovation.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization PROCEPT BioRobotics
PROCEPT is the manufacturer of the AquaBeam robotic surgical system for prostate treatment. Its year-over-year performance reflects rapid growth and the adoption of its technology in clinical practice. The chart below tells the story of this medical technology leader.
Annual dynamics of market capitalization of the market segment - Therapeutic medical equipment
PROCEPT BioRobotics Corp. has developed the AquaBeam robotic system for the treatment of benign prostatic hyperplasia. Its technology is changing approaches to urology. The chart below shows how its innovations, rapid adoption, and competition in the medical device sector are impacting its growth.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
PROCEPT BioRobotics, with its urological surgery robot, is a growth story in medicine. Its stock price is driven not by the economy, but by the speed of hospital adoption. The chart reflects how breakthrough technology can create and capture a new multi-billion dollar market, regardless of the economic climate.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization PROCEPT BioRobotics
PROCEPT, the manufacturer of the AquaBeam robotic system for prostate treatment. The monthly fluctuations on the graph reflect the pace of adoption of this new technology in hospitals and its potential to become a standard of care.
Monthly dynamics of market capitalization of the market segment - Therapeutic medical equipment
The surgical robotics market is one of the fastest-growing in the medical technology sector. Its market capitalization dynamics, shown in the chart, reflect investor enthusiasm for innovative treatment methods. Riding this wave, companies like PROCEPT BioRobotics are implementing their technologies into clinical practice.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
PROCEPT BioRobotics develops robotic systems for urology. Like many companies in the medical equipment sector, its growth is driven by innovation and the introduction of new technologies into medicine. Its shares can outperform the market due to strong demand for its products.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization PROCEPT BioRobotics
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of benign prostatic hyperplasia. Its weekly stock price reflects the pace of hospital adoption of this technology and data on its clinical effectiveness compared to traditional methods.
Weekly dynamics of market capitalization of the market segment - Therapeutic medical equipment
PROCEPT, with its innovative robotic system, is a leader in its niche and often outperforms the broader medical equipment sector. Successful sales growth and technology adoption reports distinguish it from its competitors. The graph clearly demonstrates this award for innovation and leadership in an untapped market.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
PROCEPT BioRobotics produces a robotic system for treating prostate conditions. It's a growth story in the medical equipment sector. The chart below shows how its shares, driven by the introduction of new technology, are more volatile and outperform the broader market.
Market capitalization of the company, segment and market as a whole
PRCT - Market capitalization of the company PROCEPT BioRobotics
PROCEPT BioRobotics' market capitalization dynamics reflect the growing adoption of its Aquablation robotic system for prostate treatment. The robust growth chart demonstrates investors' confidence in its technology as a new standard of treatment. This reflects its potential to transform surgical practice and capture a large market.
PRCT - Share of the company's market capitalization PROCEPT BioRobotics within the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has revolutionized the treatment of benign prostatic hyperplasia with its robotic Aquablation system. Its growing market share reflects the clinical superiority of this technology over traditional methods.
Market capitalization of the market segment - Therapeutic medical equipment
Here's a graph showing the market capitalization of the robotic surgery sector. PROCEPT BioRobotics is a leader in the robotic prostate adenoma treatment niche. The growth you see in this market is driven by the introduction of its AquaBeam system. This is an example of how innovative technology can create and capture an entirely new medical market.
Market capitalization of all companies included in a broad market index - GURU.Markets
PROCEPT BioRobotics has developed a robotic system for treating prostate conditions. Its market capitalization reflects the adoption of robotics in urology. The chart below shows the potential economic impact of a company automating complex surgical procedures.
Book value capitalization of the company, segment and market as a whole
PRCT - Book value capitalization of the company PROCEPT BioRobotics
PROCEPT BioRobotics' foundation is its intellectual property and manufacturing capabilities for the AquaBeam robotic system, used to treat prostate conditions. The chart shows how the company is expanding its resources to commercialize this innovative medical technology and expand its applications.
PRCT - Share of the company's book capitalization PROCEPT BioRobotics within the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has created a robotic system for urology. The chart shows its share of real assets. These include its R&D centers and production lines, where AquaBeam robots are being assembled, changing the standards of surgical treatment.
Market segment balance sheet capitalization - Therapeutic medical equipment
PROCEPT BioRobotics produces AquaBeam surgical robots. This is a capital-intensive business, requiring R&D centers for development and factories for assembling these complex systems, as well as inventories of disposable components. In the medical device sector, it is an example of a company creating complex hardware.
Book value of all companies included in the broad market index - GURU.Markets
PROCEPT BioRobotics' assets are not drugs, but innovative Aquablation surgical robots, which are changing the standard of prostate treatment. The company's balance sheet reflects the value of this unique technology and its installed base of robots. The chart shows the capital invested in urological robotics.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - PROCEPT BioRobotics
PROCEPT BioRobotics has developed a robotic system for treating prostate conditions. Its market value is many times higher than its book value, as investors value patents, clinical data, and the potential to change surgical standards, not just robots in a warehouse. The chart demonstrates the market's confidence in this medical technology.
Market to book capitalization ratio in a market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed a robot for surgical treatment of prostate diseases. The company's value lies in its unique technology and patents. This chart shows the enormous premium investors pay for innovation and the potential to change the standard of care, rather than for the robots' assembly lines.
Market to book capitalization ratio for the market as a whole
PROCEPT BioRobotics has developed a robotic system for treating prostate conditions. Like many medtech companies, its valuation is based on its unique technology and patents. This chart demonstrates the high premium investors pay for innovative medical equipment that could change the standard of care.
Debts of the company, segment and market as a whole
PRCT - Company debts PROCEPT BioRobotics
PROCEPT BioRobotics develops robotic systems for urological surgery. Commercializing advanced medical equipment requires significant investments in manufacturing, physician training, and marketing. Debt capital is an important resource for the company to accelerate the implementation of its technology into clinical practice worldwide.
Market segment debts - Therapeutic medical equipment
PROCEPT BioRobotics develops robotic systems for urological surgery. This is a rapidly growing medical technology sector that requires investment in R&D and commercialization. This chart shows how the company is funding its expansion and technological development: through revenue from sales of its systems or by raising debt capital to accelerate market penetration.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio PROCEPT BioRobotics
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of benign prostatic hyperplasia. This chart shows how the company is funding the commercialization of its innovative technology. This funding is being used to expand its sales and marketing department to convince hospitals and surgeons of the benefits of its system.
Market segment debt to market segment book capitalization - Therapeutic medical equipment
PROCEPT BioRobotics develops robotic systems for urological surgery. This chart reflects debt trends in the high-tech medical equipment sector. It helps understand how the company finances its innovation and market entry compared to other medical robot manufacturers, where competition and R&D costs are high.
Debt to book value of all companies in the market
PROCEPT BioRobotics, a developer of medical robots, requires investment in R&D. This chart reflects debt trends across the economy. It helps understand how the high-tech medical technology sector, often financed by equity, differs from the broader market, where debt financing plays a larger role.
P/E of the company, segment and market as a whole
P/E - PROCEPT BioRobotics
For PROCEPT BioRobotics, the developer of a robotic system for treating prostate conditions, this chart is an assessment of the future of surgery. The high price per dollar of profit indicates that investors see enormous potential in their technology. The dynamics of the indicator reflect the speed of robotic adoption in hospitals and the belief in its superiority over traditional methods.
P/E of the market segment - Therapeutic medical equipment
This chart shows the average valuation for the medical device industry—the benchmark for PROCEPT. Comparing the valuation of this robotic surgery company with the broader sector average helps us understand the significant premium investors are willing to pay for its innovative technology and potential to change the standard of care.
P/E of the market as a whole
PROCEPT BioRobotics has developed the Aquablation robotic system for the treatment of benign prostatic hyperplasia. The company is in the phase of active commercial growth. This chart of overall investor risk appetite in the medical technology sector shows whether investors are willing to pay premium prices for stocks of companies that are changing surgical standards but have yet to achieve profitability.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company PROCEPT BioRobotics
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of prostate conditions. The company's growth depends on the adoption of this technology in urological practice. This chart shows analysts' estimates of the robot's adoption by surgeons and hospitals, which directly impacts future sales and profitability forecasts.
%20P%2FE%20PROCEPT%20BioRobotics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-PROCEPT-BioRobotics&v=1772513462775 "Chart of the company's future (projected) P/E PROCEPT BioRobotics")
Future (projected) P/E of the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of benign prostatic hyperplasia. Its ranking relative to other medical device companies demonstrates the market's confidence in the superiority of its technology. This high ranking reflects expectations for the system's rapid adoption in clinical practice.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Therapeutic-medical-equipment&v=1772513462785 "Future (projected) P/E graph of the market segment - Therapeutic medical equipment")
Future (projected) P/E of the market as a whole
PROCEPT BioRobotics has developed the Aquablation robotic system for prostate treatment. The company's success depends on the adoption of this technology in hospitals. This chart shows the overall market sentiment that influences capital expenditures at medical institutions. It helps understand whether hospitals are willing to invest in expensive new equipment, even if it improves outcomes.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513462801 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit PROCEPT BioRobotics
PROCEPT BioRobotics has developed the AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia. The company's financial results, shown here, depend on the pace of adoption of this technology in hospitals. The number of systems sold and procedures performed determines its growth.
Profit of companies in the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of prostate conditions. This graph shows the overall profitability of the therapeutic medical device sector. It helps understand how quickly and readily the medical community embraces new robotic technologies, which is key to PROCEPT's success.
Overall market profit
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of prostate diseases. This is an innovative product on the medical equipment market. Its success depends on the technology's implementation in hospitals and proven clinical effectiveness. The overall economic environment, reflected in the graph, influences clinic budgets, but the primary factor is the demand for advanced treatment methods.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company PROCEPT BioRobotics
PROCEPT BioRobotics has developed the Aquablation robotic system for the treatment of prostate conditions. The company's future profitability depends on the rapid adoption of this new technology in hospitals worldwide. This chart shows analysts' confidence that this system will become the new standard in urology, ensuring stable revenue growth for the company.
%20profit%20of%20the%20company%20PROCEPT%20BioRobotics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-PROCEPT-BioRobotics&v=1772513462898 "Graph of future (projected) profit of the company PROCEPT BioRobotics")
Future (predicted) profit of companies in the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the AquaBeam robotic system for minimally invasive surgery to treat benign prostatic hyperplasia. This chart shows forecasts for the therapeutic medical device sector. It helps assess the growth potential of PROCEPT's innovative robotic surgery system against overall industry expectations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Therapeutic-medical-equipment&v=1772513462903 "Graph of future (predicted) profits of companies in a market segment - Therapeutic medical equipment")
Future (predicted) profit of the market as a whole
PROCEPT BioRobotics has developed the Aquablation robotic system for the treatment of prostate conditions. This projected profitability is impacting hospital budgets for new equipment purchases. Economic growth allows medical institutions to invest in advanced technologies that improve patient outcomes and increase surgical efficiency.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513462919 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - PROCEPT BioRobotics
PROCEPT BioRobotics has developed a robotic system for treating prostate conditions. This chart shows the high premium investors are paying for each dollar of its rapidly growing revenue. This reflects the belief that its technology will become a new standard in urology.
P/S market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the Aquablation robotic system for minimally invasive treatment of benign prostatic hyperplasia. This chart shows the average valuation in the therapeutic medical equipment sector. It reflects the premium the market is willing to pay for this innovative technology, which has the potential to become a new standard of treatment.
P/S of the market as a whole
PROCEPT BioRobotics has developed the AquaBeam robotic system for minimally invasive surgery to treat prostate conditions. The company's revenue is growing as hospitals adopt this technology. This chart provides investors with context for assessing the premium the market is willing to pay for innovations in medical robotics.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company PROCEPT BioRobotics
PROCEPT BioRobotics has developed the Aquablation robotic system for the treatment of benign prostatic hyperplasia. Future revenue depends on the adoption of this technology in clinics. The chart shows how the market perceives the potential of this innovative procedure to become a new standard of treatment and drive rapid sales growth.
%20P%2FS%20PROCEPT%20BioRobotics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-PROCEPT-BioRobotics&v=1772513462954 "The graph of the company's future (projected) P/S PROCEPT BioRobotics")
Future (projected) P/S of the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the Aquablation robotic system for minimally invasive treatment of benign prostatic hyperplasia (BPH). Its future depends on the adoption of this technology in urological practice. This chart shows how the market assesses the sales potential of this innovative system compared to other medical devices.
%20P%2FS%20market%20segment%20graph%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Therapeutic-medical-equipment&v=1772513462980 "Future (projected) P/S market segment graph - Therapeutic medical equipment")
Future (projected) P/S of the market as a whole
This indicator demonstrates the market's faith in medical technology. For PROCEPT BioRobotics, the developer of a robotic system for prostate treatment, it indicates the acceptance of innovation. Market optimism helps fund the implementation of new surgical technologies that promise better outcomes for patients and greater efficiency for hospitals.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513462999 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales PROCEPT BioRobotics
PROCEPT BioRobotics has developed the Aquablation robotic system for minimally invasive treatment of benign prostatic hyperplasia (BPH). This chart shows revenue from sales of the robots and disposable consumables. Growing sales indicate the adoption of this technology in clinics as a new standard of surgical treatment.
Sales of companies in the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of benign prostatic hyperplasia. This graph illustrates the growth of the therapeutic medical equipment market. PROCEPT's innovative technology offers a minimally invasive alternative to traditional surgery, changing the standard of care in urology.
Overall market sales
PROCEPT BioRobotics has developed the AquaBeam robotic system for the treatment of benign prostatic hyperplasia. Demand for their technology depends on the implementation of innovations in hospitals. The overall economic environment, shown in this graph, influences the capital budgets of medical institutions and their willingness to invest in new, expensive equipment.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company PROCEPT BioRobotics
PROCEPT BioRobotics has developed the Aquablation robotic system for minimally invasive treatment of benign prostatic hyperplasia (BPH). The company's growth depends on the adoption of this technology in urological practice. This chart shows analysts' forecasts for the speed of surgeon adoption and market penetration of the new technology.
%20sales%20of%20the%20company%20PROCEPT%20BioRobotics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-PROCEPT-BioRobotics&v=1772513463033 "Schedule of future (projected) sales of the company PROCEPT BioRobotics")
Future (projected) sales of companies in the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the Aquablation robotic system for minimally invasive treatment of benign prostatic hyperplasia. The forecast reflects expectations for the therapeutic medical equipment sector. It shows the expected growth in demand for robotic surgery, which is a key driver for the adoption of PROCEPT technology.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Therapeutic-medical-equipment&v=1772513463035 "Schedule of future (projected) sales of companies in the market segment - Therapeutic medical equipment")
Future (projected) sales of the market as a whole
PROCEPT BioRobotics has developed the Aquablation robotic system for minimally invasive treatment of benign prostatic hyperplasia. Its success depends on the adoption of this technology in clinical practice. This trend, reflecting the overall economic situation, affects hospitals' ability to invest in expensive new equipment to improve treatment quality.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513463046 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality PROCEPT BioRobotics
PROCEPT BioRobotics has developed the Aquablation robotic system for the treatment of prostate diseases. This graph shows the economics of implementing this new medical technology. Profitability depends on sales of the robots themselves and, more importantly, on the regular purchase of disposable consumables by clinics for each procedure.
Market segment marginality - Therapeutic medical equipment
PROCEPT BioRobotics has developed the AquaBeam robotic system for minimally invasive treatment of benign prostatic hyperplasia. Profitability depends on sales of the robots and their consumables. This chart shows the operating efficiency of this innovative business model compared to other medical robot manufacturers.
Market marginality as a whole
PROCEPT BioRobotics has developed the Aquablation robotic system for minimally invasive treatment of benign prostatic hyperplasia. This overall market profitability graph does not impact the company. Its success depends on the adoption of the technology in hospitals and the demonstration of its advantages over traditional treatment methods, which creates its own high-margin market.
Employees in the company, segment and market as a whole
Number of employees in the company PROCEPT BioRobotics
PROCEPT BioRobotics has developed the Aquablation robotic system for the treatment of benign prostatic hyperplasia. The chart shows the team commercializing this technology. The growth in staff reflects efforts to implement the system in hospitals and train surgeons.
Share of the company's employees PROCEPT BioRobotics within the market segment - Therapeutic medical equipment
PROCEPT BioRobotics has revolutionized prostate adenoma treatment with its AquaBeam robotic system. This chart shows the percentage of robotics engineers, clinical specialists, and commercial staff the company attracts in this niche medical technology field. It reflects its leadership through its concentration of talent to advance innovative surgical technology.
Number of employees in the market segment - Therapeutic medical equipment
PROCEPT BioRobotics Corporation has developed the AquaBeam robotic system for minimally invasive surgery for benign prostatic hyperplasia (BPH). This chart reflects employment growth in the therapeutic medical equipment sector, demonstrating how surgical robotics is improving treatment outcomes and creating demand for new specialists.
Number of employees in the market as a whole
PROCEPT BioRobotics has developed the Aquablation robotic system for treating prostate conditions. This is an example of how automation and robotics are entering medicine, increasing the precision and efficiency of surgeries. The growth of such companies is creating a demand for engineers, clinicians, and IT specialists, changing the face of the healthcare labor market.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics has developed the AquaBeam robotic system for prostate treatment. This chart shows how the market values medical innovations. The very high market capitalization per employee reflects the value of unique technology and patents that could change the standard of care and capture a large market.
%20of%20the%20company%20PROCEPT%20BioRobotics%20(PRCT)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-PROCEPT-BioRobotics-PRCT&v=1772513463139 "Chart of market capitalization per employee (in thousands of dollars) of the company PROCEPT BioRobotics (PRCT)")
Market capitalization per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
PROCEPT BioRobotics (PRCT) has developed the AquaBeam robotic system for the treatment of benign prostatic hyperplasia (BPH). This is high-tech medicine. This graph shows the average industry cost per employee. It helps estimate the premium the market pays for their innovative robotic technology per engineer.
%20by%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Therapeutic-medical-equipment&v=1772513463162 "Market capitalization per employee (in thousands of dollars) by market segment - Therapeutic medical equipment")
Market capitalization per employee (in thousands of dollars) for the overall market
PROCEPT BioRobotics developed the AquaBeam robotic system for minimally invasive surgery. This graph reflects the average value the market assigns to one employee. It demonstrates the high premium the market places on innovative medical technologies that change the standard of care.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513463173 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics developed a robot (AquaBeam) for surgical treatment of prostate diseases. It sells medical equipment (robots) and consumables for them. This chart shows how effectively their engineers and sales team generate profits by introducing new, expensive technology to hospitals.
%20Chart%20PROCEPT%20BioRobotics%20(PRCT)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-PROCEPT-BioRobotics-PRCT&v=1772513463182 "Company Profit Per Employee (in thousands of dollars) Chart PROCEPT BioRobotics (PRCT)")
Profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment
PROCEPT (PRCT) is a medical technology company that created a "robot" (AquaBeam) for prostate treatment. This chart shows the benchmark for "Therapeutic Equipment." The average profit per employee in this sector is high. It's a "razor and blade business." The benchmark reflects stable, high-margin revenue from "blades" (disposable consumables).
%20in%20the%20market%20segment%20-%20Therapeutic%20medical%20equipment&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Therapeutic-medical-equipment&v=1772513463186 "Chart of profit per employee (in thousands of dollars) in the market segment - Therapeutic medical equipment")
Profit per employee (in thousands of dollars) for the market as a whole
PROCEPT BioRobotics is a medical technology company that developed the AquaBeam robotic system for the treatment of prostate conditions (BPH). It operates a business based on the sale of equipment (robots) and consumables. This chart shows the company's success in installing its robots in hospitals and increasing sales of high-margin consumables per employee.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513463196 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics has developed the Aquablation robotic system for the treatment of prostate diseases. This graph demonstrates the success of commercializing this cutting-edge medical technology. The growth in this indicator reflects the system's adoption in clinics and the team's effectiveness in training surgeons and selling consumables.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-PROCEPT-BioRobotics-PRCT&v=1772513463203 "Sales chart per company employee PROCEPT BioRobotics (PRCT)")
Sales per employee in the market segment - Therapeutic medical equipment
PROCEPT BioRobotics developed the AquaBeam system—a robotic surgery system for urology (treatment of prostate adenoma). This is innovative medical technology. This graph shows the average revenue per employee in this segment. It helps evaluate how effectively PROCEPT's team (R&D, sales) is implementing its robots in clinics compared to competitors.
Sales per employee for the market as a whole
PROCEPT BioRobotics developed the AquaBeam robotic system for urological surgery. They sell high-end medical equipment. This chart is key. It shows how effectively their team (engineers, but primarily sales and clinical specialists) sells and services these innovative robotic systems.
Short shares by company, segment and market as a whole
Shares shorted by company PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics has developed a robot (AquaBeam) for the surgical treatment of prostate adenoma. The technology is innovative, but the company must convince hospitals to purchase expensive equipment and compete with other methods. This chart demonstrates investor skepticism regarding the speed of adoption of the robot or its real advantages over existing procedures.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-PROCEPT-BioRobotics-PRCT&v=1772513463255 "Short Shares Chart for the Company PROCEPT BioRobotics (PRCT)")
Shares shorted by market segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the AquaBeam robotic system, which uses a high-pressure water jet to treat benign prostatic hyperplasia (BPH). This chart illustrates the overall bearish sentiment in the therapeutic medical equipment sector. The rising figure may indicate that investors expect a slowdown in the adoption of new, expensive robotic systems in hospitals.
Shares shorted by the overall market
PROCEPT (PRCT) is a manufacturer of robots (AquaBeam) for urological surgery. This Short_All chart is a fear meter. When it rises, it signals two threats: investors are dumping growth stocks (medtech), and recession fears are causing hospitals to delay purchasing expensive robots.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics is the creator of the AquaBeam system, a robotic prostate surgery system. Like many medtech companies, their stock is driven by expectations for the technology's adoption. This chart shows when investor enthusiasm for robot sales growth (overbought) or concerns about competition (oversold) reach extremes, reflecting the strength of market momentum.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-PROCEPT-BioRobotics-PRCT&v=1772513463301 "RSI 14 indicator chart for the company's stock PROCEPT BioRobotics (PRCT)")
RSI 14 Market Segment - Therapeutic medical equipment
PROCEPT BioRobotics has developed the AquaBeam system, a robotic surgical system for treating benign prostatic hyperplasia (BPH) using a water jet. This is a breakthrough innovation in urology. This graph measures the overall momentum in the robotic surgery sector. It helps assess whether this high-tech segment is overheating with the introduction of new technologies.
RSI 14 for the overall market
PROCEPT BioRobotics (PRCT) produces robots for urological surgeries. This graph reflects hospitals' willingness to make expensive capital expenditures. During periods of euphoria and budget increases, clinics eagerly purchase innovative equipment. During moments of panic and cost-cutting, these multimillion-dollar purchases are postponed indefinitely.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast PRCT (PROCEPT BioRobotics)
PROCEPT BioRobotics has developed the AquaBeam system—a robotic, water-powered surgery for the treatment of benign prostatic hyperplasia (BPH). This graph reflects analyst consensus on how quickly hospitals will adopt this new technology.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-PRCT-PROCEPT-BioRobotics&v=1772513463411 "A chart showing analyst consensus forecasts for the expected stock price. PRCT (PROCEPT BioRobotics)")
The difference between the consensus estimate and the actual stock price PRCT (PROCEPT BioRobotics)
PROCEPT BioRobotics (PRCT) has developed the AquaBeam robot for the treatment of benign prostatic hyperplasia (BPH) using aqua ablation (water jet). This chart shows the evaluation of their technology. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their robotic system.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-PRCT-PROCEPT-BioRobotics&v=1772513463420 "A chart showing the difference between the consensus forecast and the actual stock price. PRCT (PROCEPT BioRobotics)")
Analyst consensus forecast for stock prices by market segment - Therapeutic medical equipment
PROCEPT BioRobotics is a medical company that developed the AquaBeam robotic system for non-surgical treatment of benign prostatic hyperplasia (BPH) using a water jet. This chart shows general expectations for the therapeutic medical equipment sector. It reflects whether experts believe this new technology will be widely adopted by urologists.
Analysts' consensus forecast for the overall market share price
PROCEPT BioRobotics (PRCT) is the manufacturer of the AquaBeam robot for prostate surgery (treatment of benign prostatic hyperplasia). This chart of overall market sentiment is important. Optimism means hospitals (their clients) are actively investing in expensive new equipment (robots). During a recession (pessimism), these capital expenditures are frozen.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index PROCEPT BioRobotics
PROCEPT BioRobotics (PRCT) is the company behind the AquaBeam robot, which uses waterjet technology (aqua ablation) to treat benign prostatic hyperplasia (BPH). This chart evaluates the adoption of their robot. It measures their ability to sell the robot to hospitals and, more importantly, generate recurring revenue from consumable sales.
AKIMA Market Segment Index - Therapeutic medical equipment
PROCEPT BioRobotics (PRCT) is a medical technology innovator that created the AquaBeam robot, the first robotic system to use a pressurized water jet to treat BPH (prostate enlargement). This composite metric evaluates companies. The graph shows the sector average. This benchmark provides insight into how PROCEPT's breakthrough robotic technology differentiates it from its average medical technology competitor.
The AKIM Index for the overall market
PROCEPT BioRobotics is a medtech company that developed the AquaBeam robotic system for treating benign prostatic hyperplasia (BPH) using a water jet. This chart, reflecting the market average, provides context. It helps to assess how this rapid adoption of this technology in urology compares to the overall macroeconomic trends affecting medicine.
